About pcm

Manuscript Submission

AME Editing Service

Reprint & Permission

Advertising

Contact us

Editorial Commentary 
PARP inhibitors beyond BRCA-mutated cancers: precision medicine at the crossroads
Bartłomiej Tomasik, Michał Bieńkowski, Jacek Jassem
Precision Cancer Medicine  
2021;
4:
19  
Editorial Commentary 
Lung cancer screening: think pink!
Monica Casiraghi, Lorenzo Spaggiari
Precision Cancer Medicine  
2021;
4:
18  
Case Report 
Effectiveness of pemetrexed-based chemotherapy and radiation therapy in RET-rearranged lung adenocarcinoma: a mono-institutional case series
Fabrizio Citarella, Marco Russano, Alessandro Galletti, Giuseppina-Rita Di Fazio, Bruno Vincenzi, Giuseppe Tonini, Daniele Santini
Precision Cancer Medicine  
2021;
4:
17  
Review Article 
ROS-1 NSCLC therapy resistance mechanism
Miguel García-Pardo, Antonio Calles
Precision Cancer Medicine  
2021;
4:
16  
Review Article 
Monitoring therapeutic response and resistance with liquid biopsy
Virginia Calvo, Atocha Romero, Mariano Provencio
Precision Cancer Medicine  
2021;
4:
15  
Review Article 
Non-small cell lung cancer molecular characterization of advanced disease with focus on sex differences: a narrative review
Rossella Bruno, Greta Alì, Anello Marcello Poma, Gabriella Fontanini
Precision Cancer Medicine  
2021;
4:
14  
Review Article 
A narrative review of chemotherapy in advanced triple negative breast cancer
Maria L. Romero Lagunes, Rossanna C. Pezo
Precision Cancer Medicine  
2021;
4:
13  
Review Article 
Triple negative breast cancer: emerging light on the horizon—a narrative review
Umangjot K. Bharaj, Ana E. Lohmann, Phillip S. Blanchette
Precision Cancer Medicine  
2021;
4:
12  
Original Article 
The use of stereotactic body radiotherapy in pulmonary carcinoid tumors: a case series
Katharine Thomas, Chris Smith, Andrew Marsala, John Philip Boudreaux, Ramcharan Thiagarajan, Robert A. Ramirez
Precision Cancer Medicine  
2021;
4:
11  
Editorial Commentary 
BRAF V600E mutant, PD-L1 TPS 90% NSCLC: 1st line treatment with targeted therapy
Edwin H. Yau
Precision Cancer Medicine  
2021;
4:
10  
Editorial Commentary 
The role of Anti-PD-1/PD-L1 monotherapy as first-line treatment of metastatic NSCLC without targetable mutations and PD-L1 TPS 1–49%
Arpeet T. Shah, Joel W. Neal
Precision Cancer Medicine  
2021;
4:
9  
Editorial Commentary 
Management of acquired resistance to ALK inhibitors: repeat biopsy to characterize mechanisms of resistance does not significantly impact clinical outcomes
Naiyarat Prasongsook, Thanyanan Reungwetwattana
Precision Cancer Medicine  
2021;
4:
8  
Editorial Commentary 
Concerns and controversies regarding ipilimumab-based immunotherapy in the first-line treatment of non-small cell lung cancer
Ivy Riano, Narjust Duma
Precision Cancer Medicine  
2021;
4:
7  
Editorial Commentary 
ADAURA: The role of adjuvant EGFR TKI and future consideration (Pro)
Patrick C. Ma
Precision Cancer Medicine  
2021;
4:
6  
Case Report 
Precision oncology in EGFR positive non-small cell lung cancer: breaking the 10-year barrier—a case report
Camila Ordóñez-Reyes, Alejandro Ruiz-Patiño, Oscar Arrieta, Lucia Zatarain-Barrón, Leonardo Rojas, Gonzalo Recondo, Luisa Ricaurte, Andrés F. Cardona, on behalf of Latin American Consortium for the Investigation of Lung Cancer (CLICaP)
Precision Cancer Medicine  
2021;
4:
5  
Case Report 
Unusual pattern of recurrence and atypical visceral metastases in extremity soft tissue sarcoma: a case report
Paula Sedano, Carmen González-San Segundo, Marta Rodríguez-Pertierra, Francisco Díaz-Gutiérrez, Adriana Medrano, Carolina Agra-Pujol
Precision Cancer Medicine  
2021;
4:
4  
Review Article 
A narrative review of immune checkpoint inhibitors in early stage triple negative breast cancer
Ana-Alicia Beltran-Bless, Terry L. Ng
Precision Cancer Medicine  
2021;
4:
3  

Editorial

AR-V7 and treatment selection in advanced prostate cancer: are we there yet?
Diogo A. Bastos, Emmanuel S. Antonarakis

Case Report: Precision Oncology Tumor Board

Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond?
Kartik Sehgal, Andrew J. Piper-Vallillo, Hollis Viray, Adeel M. Khan, Deepa Rangachari, Daniel B. Costa